CELL MEMBRANE COATED POLYMERIC NANOCARRIERS: A NOVEL DRUG DELIVERY APPROACH FOR THE TARGETED THERAPY OF RHEUMATOID ARTHRITIS

Abstract

Rheumatoid arthritis is a chronic inflammatory disorder that affects the joints and can lead to significant disability. RA may affect other parts of the body, leading to various issues including damage to the joints, deformity, disability, and reduced mobility. The pathogenesis of RA involves a complex interplay between genetic, environmental and immunological factors. The treatment of rheumatoid arthritis typically reduces inflammation, manages pain, stiffness and prevents joint damage. However, these medications have several side effects no single therapeutic remedy directly targets the disease. Researchers in the field are focused on developing new treatments that are more effective and have fewer side effects as well as understanding the underlying mechanisms of the disease. Some areas of current research include the use of nanotechnology such as cell membrane-coated nanoparticles for the treatment of RA as well as the development of new biologic drugs that target specific molecules involved in inflammation. The use of cell membrane-coated nanoparticles for the treatment of rheumatoid arthritis has several potential benefits including targeted drug delivery, reduced inflammation, improved safety and biocompatibility, and reduced frequency of administration. However, more research is needed to fully understand the potential benefits and limitations of this approach to develop effective cell membrane coated nanoparticle-based therapies for RA. In this review cell membrane-coated nanoparticles may become valuable for numerous biomedical problems.